Segment Information
Selected financial and descriptive information is required to be provided about reportable operating segments, considering a “management approach” concept as the basis for identifying reportable segments. The management approach is based on the way that management organizes the segments within the Company for making operating decisions, allocating resources, and assessing performance. Consequently, the segments are evident from the structure of the Company’s internal organization, focusing on financial information that the Company’s CEO uses to make decisions about the Company’s operating matters.
As described in Note 1, SWK Holdings Corporation and Summary of Significant Accounting Policies, the Company has determined it has two reportable segments: Finance Receivables and Pharmaceutical Development, and each are individually managed and provide separate services. Revenues by segment represent revenues earned on the services offered within each segment. The Company does not report results by geographic region, as this metric is not used by the Company’s chief executive officer in assessing performance or allocating resources to the segments. All revenues are generated through external customers.
Segment performance is evaluated based on several factors, including income (loss) from continuing operations before income taxes. Management uses this measure of profit (loss) to evaluate segment performance because the Company believes this measure is indicative of performance trends and the overall earnings potential of each segment. The Company does not report assets by reportable segment, as this metric is not used by the Company's CEO in assessing performance or allocating resources to the segments. As of December 31, 2024, Enteris is classified as held for sale (Pharmaceutical Development segment shown below) - see Note 7 for further details.
The following tables present financial information for the Company’s reportable segments for the periods indicated (in thousands):
| | | | | | | | | | | | | | | | | | | | | | | |
| Year Ended December 31, 2024 |
| Finance Receivables | | Pharmaceutical Development and Other | | Holding Company and Other | | Consolidated |
| Revenue | $ | 40,787 | | | $ | 3,616 | | | $ | — | | | $ | 44,403 | |
| Other revenue | 553 | | | 31 | | | — | | | 584 | |
| Provision for credit losses | 12,756 | | | — | | | — | | | 12,756 | |
| Loss on impairment of intangible assets | — | | | 5,771 | | | — | | | 5,771 | |
| Interest expense | 1,078 | | | 8 | | | 3,599 | | | 4,685 | |
| Pharmaceutical manufacturing, research and development | — | | | 2,203 | | | — | | | 2,203 | |
| Change in fair value of acquisition-related contingent consideration | — | | | (4,900) | | | — | | | (4,900) | |
| Depreciation and amortization expense | — | | | 1,316 | | | 83 | | | 1,399 | |
| General and administrative expense | 449 | | | 2,967 | | | 8,071 | | | 11,487 | |
| Other income (expense), net | 7,194 | | | — | | | (408) | | | 6,786 | |
| Income tax expense | — | | | — | | | 4,884 | | | 4,884 | |
| Net income (loss) | 34,251 | | | (3,718) | | | (17,045) | | | 13,488 | |
| | | | | | | | | | | | | | | | | | | | | | | |
| Year Ended December 31, 2023 |
| Finance Receivables | | Pharmaceutical Development and Other | | Holding Company and Other | | Consolidated |
| Revenue | $ | 36,346 | | | $ | 1,202 | | | $ | — | | | $ | 37,548 | |
| Other revenue | 204 | | | 2 | | | 6 | | | 212 | |
| Provision for credit losses | 1,912 | | | — | | | — | | | 1,912 | |
| Impairment of goodwill | — | | | 8,404 | | | — | | | 8,404 | |
| Interest expense | 982 | | | 3 | | | 864 | | | 1,849 | |
| Pharmaceutical manufacturing, research and development expense | — | | | 3,436 | | | — | | | 3,436 | |
| Depreciation and amortization expense | — | | | 2,525 | | | 52 | | | 2,577 | |
| Change in fair value of acquisition-related contingent consideration | — | | | (6,300) | | | — | | | (6,300) | |
| General and administrative expense | 527 | | | 2,875 | | | 7,830 | | | 11,232 | |
| Other expense, net | (13) | | | (24) | | | — | | | (37) | |
| Income tax benefit | — | | | — | | | (1,274) | | | (1,274) | |
| Net income (loss) | 33,116 | | | (9,763) | | | (7,466) | | | 15,887 | |
Included in Holding Company and Other are the expenses of the parent holding company and certain other enterprise-wide overhead costs, including public company costs and non-Enteris corporate employees, which have been included for purposes of reconciling to the consolidated amounts.
The following table presents total assets for the Company's reportable segments for the periods indicated (in thousands):
| | | | | | | | | | | |
| December 31, |
| 2024 | | 2023 |
| Total Assets | | | |
| Finance Receivables | $ | 299,248 | | | $ | 288,735 | |
| Pharmaceutical Development and Other | 7,786 | | | 14,375 | |
| Holdings Company and Other | 25,201 | | | 31,144 | |
| Total | $ | 332,235 | | | $ | 334,254 | |
About Segments Disclosures
Segment disclosures break a company into its reportable operating units, revealing revenue, profit, and asset allocation that consolidated financial statements obscure. Under ASC 280, segments must match how the chief operating decision maker views the business, providing a window into internal management structure and resource allocation priorities.
Key signals: compare segment margins to identify which units drive profitability and which destroy value. Watch for changes in the number of reportable segments — segment aggregation or disaggregation often coincides with strategic shifts or attempts to obscure declining performance. Intersegment elimination patterns reveal internal pricing practices. The reconciliation between segment totals and consolidated figures exposes corporate overhead allocation and unallocated items. Geographic revenue concentration highlights regulatory and currency exposure. Compare segment-level capital expenditure against segment revenue to assess where management is investing for future growth versus harvesting existing assets.